Quality Assurance Associate at Drugstoc E-hub Limited | Careersngr : Careersngr

Advertisements

Quality Assurance Associate at Drugstoc E-hub Limited

Filed in by on January 26, 2023
Full Time Jobs in Nigeria
JOBS IN LAGOS STATE - JOB VACANCIES IN LAGOS STATE NIGERIA
Posted 1 year ago

Drugstoc is inviting credible applicants who are willing to partake in its ongoing recruitment to fill the position below:

Job Title: Quality Assurance Associate

Advertisements

Location: Ojota, Lagos
Employment Type: Full-time

 About Drugstoc: Drugstoc is a pharmaceutical distribution company engaged in the acquiring and distribution of pharmaceutical and healthcare products to healthcare facilities and licensed practitioners. Drugstoc exists to empower all healthcare providers fulfill their mandate for a healthier Africa.

Job Requirements

  • Bachelor’s Degree
  • Minimum of 3 years’ experience in a Quality Management position
  • Proven experienced with Audit and stock taking activity
  • A keen eye for detail and a result driven approach
  • Outstanding communication skills
  • Excellent organizational and leadership skills
  • Proficient in MS Office
  • In depth Understanding of quality procedures.
  • Certification and/or knowledge of quality control procedures according to ISO 9001 is an added advantage.
  • He/she must have a proper understanding of 6sigma. Preferably the DMAIC methodology
  • Decision making skills.
  • Collaborative skills
  • Highly organized and detail oriented
  • Multi-tasking and time-management skills, with the ability to prioritize tasks.
  • A ‘change the world’ mindset and a can-do attitude.

  How to Submit Your Application

Interested and qualified candidates should forward their CV to: [email protected] using the Job Title as subject of the email.

Note: Only qualified candidates will be contacted.

 Application Closing Date
31st January, 2023.

Advertisements

Job Features

Job CategoryAdmin Associate, Analyst/ Quality Control, Director / Associate Partner Jobs in Nigeria

Apply Online

Comments are closed.